C.T. Fitzpatrick
Vulcan Value Partners
Vulcan Value Partners AstraZeneca PLC stake
total: 273
Vulcan Value Partners AZN-OLD trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2015 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2016 Q1
According to 2026 Q2 report, Vulcan Value Partners doesn't hold any AstraZeneca PLC (AZN-OLD) shares. To date, the estimated cost basis is nearly $33.92 for "buy" trades and estimated average "sell" price is $33.92. Vulcan Value Partners first purchased AZN-OLD in 2015 Q4, initially acquiring 6,250 shares. Since the initial investment in AstraZeneca PLC (AZN-OLD), Vulcan Value Partners has made 1 more transaction.
When did Vulcan Value Partners sell AstraZeneca PLC (AZN-OLD)?
Vulcan Value Partners sold off the entire AstraZeneca PLC (AZN-OLD) position in 2016 Q1.
When did Vulcan Value Partners buy AstraZeneca PLC (AZN-OLD)?
Vulcan Value Partners first invested in AstraZeneca PLC (AZN-OLD) in 2015 Q4 at the reported quarter-end price of $33.92 per share.
What's the cost basis of Vulcan Value Partners's AZN-OLD stake?
The estimated cost basis for AstraZeneca PLC (AZN-OLD) stake is around $33.92 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $33.92
- Weighted AVG sell price:
- $33.92
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.